Hubei Biocause Pharmaceutical (000627) — Financial Flexibility Index
Hubei Biocause Pharmaceutical (000627) has a Financial Flexibility Index of 0.00x as of September 2023. Free cash flow of CN¥286.56 Million (operating CF CN¥276.06 Million minus capex CN¥10.51 Million) represents 0% of total liabilities (CN¥272.50 Billion). Check 000627 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Hubei Biocause Pharmaceutical Financial Flexibility Index (2001–2023)
Historical Financial Flexibility Index trend for Hubei Biocause Pharmaceutical across 18 annual periods. For the full cash flow conversion analysis, see Hubei Biocause Pharmaceutical operating cash flow efficiency.
Annual Financial Flexibility Index for Hubei Biocause Pharmaceutical (2001–2023)
Year-by-year free cash flow to debt coverage for Hubei Biocause Pharmaceutical. Explore Hubei Biocause Pharmaceutical (000627) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.04x | CN¥9.60 Billion | CN¥9.53 Billion | CN¥268.30 Billion | ▲ +18.7% |
| 2022 | 0.03x | CN¥7.66 Billion | CN¥7.52 Billion | CN¥254.00 Billion | ▲ +53.1% |
| 2021 | 0.02x | CN¥4.46 Billion | CN¥4.17 Billion | CN¥226.43 Billion | ▼ -81.4% |
| 2020 | 0.11x | CN¥21.74 Billion | CN¥21.42 Billion | CN¥204.81 Billion | ▼ -38.1% |
| 2019 | 0.17x | CN¥29.32 Billion | CN¥28.60 Billion | CN¥170.92 Billion | ▲ +71.2% |
| 2018 | 0.10x | CN¥15.26 Billion | CN¥14.98 Billion | CN¥152.24 Billion | ▲ +841.3% |
| 2017 | 0.01x | CN¥1.21 Billion | CN¥431.58 Million | CN¥113.71 Billion | ▼ -22.3% |
| 2016 | 0.01x | CN¥1.34 Billion | CN¥-2.34 Billion | CN¥97.48 Billion | ▲ +243.7% |
| 2015 | -0.01x | CN¥-5.97 Million | CN¥-46.73 Million | CN¥625.50 Million | ▼ -102.5% |
| 2013 | 0.38x | CN¥274.33 Million | CN¥130.53 Million | CN¥720.71 Million | ▼ -9.7% |
| 2012 | 0.42x | CN¥222.29 Million | CN¥93.79 Million | CN¥527.37 Million | ▼ -8.5% |
| 2011 | 0.46x | CN¥216.32 Million | CN¥66.95 Million | CN¥469.47 Million | ▼ -45.7% |
| 2010 | 0.85x | CN¥317.67 Million | CN¥224.58 Million | CN¥374.25 Million | ▲ +112.3% |
| 2007 | 0.40x | CN¥183.32 Million | CN¥118.56 Million | CN¥458.52 Million | ▼ -31.3% |
| 2006 | 0.58x | CN¥258.31 Million | CN¥128.19 Million | CN¥443.66 Million | ▲ +183.8% |
| 2005 | 0.21x | CN¥73.17 Million | CN¥48.66 Million | CN¥356.70 Million | ▼ -10.1% |
| 2004 | 0.23x | CN¥81.59 Million | CN¥56.07 Million | CN¥357.41 Million | ▼ -25.0% |
| 2001 | 0.30x | CN¥68.77 Million | CN¥37.30 Million | CN¥226.09 Million | — |